Tatiana Barba

T. Barba is a clinical researcher whose recent work centres on the interface between classical psychedelics and conventional serotonergic antidepressant treatments, and on mechanistic and outcome-focused studies in depressive and anxiety disorders. Their publications and trial involvement (as recorded in the internal database) include comparative investigations of psilocybin versus escitalopram for major depression, prospective surveys of how ongoing serotonergic antidepressant use influences acute psychedelic subjective experience and clinical outcomes, analyses of the effects of antidepressant discontinuation prior to psilocybin therapy, and studies examining the impact of psilocybin on rumination and thought suppression. Methodologically, Barba is engaged in randomised-controlled approaches, prospective survey research and mixed-methods studies, reflecting an emphasis on both quantitative clinical endpoints and subjective experience measures.